We are live on ! Find out more

CBLL

CeriBell Inc

CBLL

Market cap $897M

23.37 USD

-0.08

0.34%

At close Updated Aug 27, 4:00 PM EDT

Pre-market

After hours

23.37

0.00

0%

1 day

-0.34%

5 days

-3.87%

1 month

28.9%

3 months

24.97%

6 months

25.17%

Year to date

9.72%

1 year

101.47%

5 years

-6.52%

10 years

-6.52%

About: CeriBell Inc is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform designed to address the unmet needs of patients in the acute care setting. By combining proprietary, portable, and rapidly deployable hardware with sophisticated artificial intelligence (AI)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. Its products are Point-of-Care EEG, Clarity, and EEG Portal.

Employees: 300

Healthcare Medical Devices

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 27.3%

Neutral 63.6%

Negative 9.1%

CeriBell Expands EEG Platform Beyond Seizures With Delirium, Pediatric Push

CeriBell NASDAQ: CBLL outlined its plans to expand its brainwave-monitoring platform beyond seizure detection, pointing to new products for delirium, pediatric patients and eventually stroke as it continues to build its hospital customer base.

CeriBell Expands EEG Platform Beyond Seizures With Delirium, Pediatric Push

CeriBell, Inc. (CBLL) Q2 2026 Earnings Call Transcript

CeriBell, Inc. (CBLL) Q2 2026 Earnings Call Transcript

CeriBell, Inc. (CBLL) Q2 2026 Earnings Call Transcript

Zacks Investment Research

Here's What Key Metrics Tell Us About CeriBell, Inc. (CBLL) Q2 Earnings

Although the revenue and EPS for CeriBell, Inc. (CBLL) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Here's What Key Metrics Tell Us About CeriBell, Inc. (CBLL) Q2 Earnings

Zacks Investment Research

CeriBell, Inc. (CBLL) Reports Q2 Loss, Tops Revenue Estimates

CeriBell, Inc. (CBLL) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to a loss of $0.38 per share a year ago.

CeriBell, Inc. (CBLL) Reports Q2 Loss, Tops Revenue Estimates

CeriBell Q2 Earnings Call Highlights

CeriBell NASDAQ: CBLL reported second-quarter 2026 revenue growth of 33% as increased utilization at existing hospital accounts and continued customer additions supported results. The company also raised its full-year revenue outlook and outlined plans to commercially launch its delirium-monitoring solution later this year.

CeriBell Q2 Earnings Call Highlights

Ceribell Receives FDA Clearance for Advanced Epileptiform Abnormality Detection and Artifact Reduction for Its Cloud-Based Portal, Delivering Greater Precision for Critical-Care EEG Review

SUNNYVALE, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell” or the “Company”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for two new AI algorithm enhancements integrated directly into its existing cloud-based Neurology Portal: Epileptiform Abnormality Detection and Artifact Reduction.1 These new capabilities expand the clinical utility of the Ceribell Point-of-Care (POC) brain monitoring system, providing neurologists and bedside practitioners with an enhanced toolset for rapid, high-confidence electroencephalogram (EEG) assessment.

Ceribell Receives FDA Clearance for Advanced Epileptiform Abnormality Detection and Artifact Reduction for Its Cloud-Based Portal, Delivering Greater Precision for Critical-Care EEG Review

Ceribell Secures CMS New Technology Add-On Payment (NTAP) for Breakthrough Point-of-Care Delirium Monitor System

Incremental NTAP Reimbursement Stands to Broaden Access to First-of-Its-Kind Dual Seizure and Delirium Monitoring Platform Incremental NTAP Reimbursement Stands to Broaden Access to First-of-Its-Kind Dual Seizure and Delirium Monitoring Platform

Ceribell Secures CMS New Technology Add-On Payment (NTAP) for Breakthrough Point-of-Care Delirium Monitor System

Ceribell Expands Board of Directors with Appointments of Thomas West and Sharon O'Keefe

SUNNYVALE, Calif., July 29, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced the appointments of Thomas “Tom” West and Sharon O'Keefe to its Board of Directors.

Ceribell Expands Board of Directors with Appointments of Thomas West and Sharon O'Keefe

Ceribell to Participate in the Canaccord Genuity 46th Annual Growth Conference

SUNNYVALE, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Scott Blumberg, CFO, will participate in a fireside chat at the upcoming Canaccord Genuity 46th Annual Growth Conference in Boston. The fireside chat will take place on Wednesday, August 12, 2026, at 6:00 a.m. Pacific Daylight Time / 9:00 a.m. Eastern Daylight Time.

Ceribell to Participate in the Canaccord Genuity 46th Annual Growth Conference

Ceribell to Report Second Quarter 2026 Financial Results on August 10, 2026

SUNNYVALE, Calif., July 20, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it will release financial results for the second quarter of 2026 after the close of trading on Monday, August 10, 2026. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on August 10, 2026.

Ceribell to Report Second Quarter 2026 Financial Results on August 10, 2026

See News Rankings

Price charts implemented using Lightweight Charts™